Epeius Biotechnologies Corporation
This eMediaKit™ - an electronic media kit - for Epeius Biotechnologies Corporation contains background information as well as a news archive index (below). The visionary business builders of Epeius Biotechnologies Corporation share an abiding passion for the pursuit of excellence in science focused sharply on the development of superior medicines for cancer. Founded in 2000, and incubated at The University of Southern California School of Medicine, Epeius Biotech emerged in 2002 as a free standing company with an enviable IP portfolio, a high-value tumor-targeting platform and lead product that has been validated in the crucible of clinical medicine, and revenues beginning in 2006.
Epeius Biotechnologies is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems and high-value oncology products. Credited with innovations ranging from gene discovery, therapeutic designer genes, pathotropic (disease-seeking) targeting, high-performance vector engineering, to advanced GMP & Bioprocess development,
Epeius is an acknowledged leader in the field of genetic medicine with an impressive intellectual property estate. Rapid advances in clinical development have provided Epeius with a unique opportunity for early revenues from the exportation and sale of its lead product to the Philippines and reciprocating Southeast Asian countries, thus demonstrating the high-growth potential of an innovative biotechnology company while maintaining the lowered risk profile of a biopharmaceutical company with a high-value, late-stage product.
More information for Epeius Biotechnologies Corporation:
http://www.epeiusbiotech.com/contact.asp
Subscribe to news RSS Feed for Epeius Biotechnologies Corporation Profile information is Copr. © 2012 eMediaKit™.
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announced today that the U.S. FDA has granted Phase 3 status for Company’s lead anti-cancer agent, Rexin-G, the first, and so far only, targeted gene delivery system developed to seek-out and destroy metastatic cancer.
FILED UNDER: California, Drugs and Pharmaceuticals, Medical, Pharma, Press Releases, SAN MARINO, Calif..
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation, a leader in the emerging field of targeted genetic medicine, announced today the receipt of additional financial support for the company’s lead oncology product, Rexin-G, from the U.S. Departments of Treasury, Health and Human Services (HHS), and the National Institutes of Health (NIH) in the form of a prestigious competitive grant.
FILED UNDER: Business, California, Drugs and Pharmaceuticals, Medical, Press Releases, SAN MARINO, Calif..
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation, a leader in the emerging field of targeted genetic medicine, reports the publication of a landmark paper in clinical oncology. Following up on its advanced U.S. Phase I/II clinical trials of Rexin-G in chemo-resistant metastatic pancreatic cancer (Molecular Therapy, 2010, 18: 435-441), which gained both Orphan Drug and FDA Fast Track Status, this new paper documents the molecular mechanisms-of-action of Rexin-G.
FILED UNDER: Biotechnology, California, Medical, Press Releases, SAN MARINO, Calif..
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for another crucial patent covering its leading tumor-targeted gene delivery platform. The issuance of this high-value patent protection for targeting metastatic disease follows on the heels of two major patent issuances.
FILED UNDER: California, Drugs and Pharmaceuticals, Medical, Press Releases, SAN MARINO, Calif..
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announces the results of the clinical trial entitled ‘Advanced Phase I/II Evaluation of Tumor-Targeted Gene Delivery: Intravenous Rexin-G as Stand Alone Therapy for Chemotherapy-resistant Bone and Soft Tissue Sarcoma’ at the ASCO Annual Meeting on June 8, 2010. The presentation will be discussed by Dr. Kristen N. Ganjoo, Stanford University Medical Center, Palo Alto CA.
FILED UNDER: California, Drugs and Pharmaceuticals, Medical, Press Releases, SAN MARINO, Calif..
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announces the results of the clinical study entitled ‘Phase I and II Studies of Intravenous Rexin-G as Monotherapy for Gemcitabine-resistant Metastatic Pancreas Cancer’ at the ASCO Annual Meeting on June 6, 2010. The presentation will be discussed by Dr. Howard W. Bruckner, Bruckner Oncology, New York, NY.
FILED UNDER: California, Devices and Research, Medical, Press Releases, SAN MARINO, Calif..
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announces the clinical results of the study entitled ‘A Phase I/II Study of Intravenous Rexin-G and Reximmune-C for Cancer Immunotherapy: The GeneVieve Protocol’ at the ASCO Annual Meeting on June 6, 2010. The presentation will be made by Dr. Jorge G. Ignacio, Chairman of the Cancer Institute and Bioethics Committee-Philippine General Hospital, and Principal Investigator of the study.
FILED UNDER: California, Drugs and Pharmaceuticals, Medical, Press Releases, SAN MARINO, Calif..
eMediaKit™, e-MediaKit™, and eMediaKits™ are trademarks and service marks
of Neotrope® - all rights reserved.
Created, hosted, and published in the U.S.A. Our local newswire time (ET):
Wed, 23 May 12 14:42:18 -0400.